EP2563148A1 - Composition in the form of liquid for maintenance of contact lenses and medical materials - Google Patents

Composition in the form of liquid for maintenance of contact lenses and medical materials

Info

Publication number
EP2563148A1
EP2563148A1 EP11727815A EP11727815A EP2563148A1 EP 2563148 A1 EP2563148 A1 EP 2563148A1 EP 11727815 A EP11727815 A EP 11727815A EP 11727815 A EP11727815 A EP 11727815A EP 2563148 A1 EP2563148 A1 EP 2563148A1
Authority
EP
European Patent Office
Prior art keywords
acid
composition according
hydrogen peroxide
solution
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP11727815A
Other languages
German (de)
French (fr)
Other versions
EP2563148B1 (en
Inventor
Przemyslaw Labuz
Wojciech Macyk
Grazyna Stochel
Piotr B. Heczko
Magdalena Strus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Uniwersytet Jagiellonski
Original Assignee
Uniwersytet Jagiellonski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Jagiellonski filed Critical Uniwersytet Jagiellonski
Publication of EP2563148A1 publication Critical patent/EP2563148A1/en
Application granted granted Critical
Publication of EP2563148B1 publication Critical patent/EP2563148B1/en
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
    • A01N59/16—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
    • A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/08—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing solids as carriers or diluents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/34—Shaped forms, e.g. sheets, not provided for in any other sub-group of this main group
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N31/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
    • A01N31/08—Oxygen or sulfur directly attached to an aromatic ring system
    • A01N31/16—Oxygen or sulfur directly attached to an aromatic ring system with two or more oxygen or sulfur atoms directly attached to the same aromatic ring system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
    • A01N33/02—Amines; Quaternary ammonium compounds
    • A01N33/08—Amines; Quaternary ammonium compounds containing oxygen or sulfur
    • A01N33/10—Amines; Quaternary ammonium compounds containing oxygen or sulfur having at least one oxygen or sulfur atom directly attached to an aromatic ring system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/10—Aromatic or araliphatic carboxylic acids, or thio analogues thereof; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/28—Titanium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12

Definitions

  • the subject of the present invention is a composition, especially in the form of a liquid for an external use, for treatment and maintenance of contact lenses, containing nanocrystalline photocatalyst active upon visible light illumination and eventually hydrogen peroxide.
  • the goal of the present invention is to deliver a composition for the production of solutions exhibiting sterilizing properties upon irradiation with visible light and therefore suitable for maintenance of various materials, especially those requiring physiological use, as contact lenses, medical materials (catheters, bandages, syringes, etc.).
  • the subject of the present invention is the composition containing titanium dioxide Ti0 2 modified on its surface with an organic compound selected from a group encompassing: i. a compound described by the general formula:
  • R denotes -H, -NH 2 , -NH 3 + or -S0 3 M, in which M denotes H + , K + , Na + , Li + , NH 4 + ,
  • the composition according to the invention is in the form of liquid containing a colloidal solution in which the dispersed phase is composed of the surface modified nanoparticles of titanium dioxide characterized by the particle size lower than 100 nm, while the aqueous solution of hydrogen peroxide plays the role of the dispersion medium.
  • the composition according to the present invention exhibits visible light absorption as well as photocatalytic activity in a wavelength range ( ⁇ ) no smaller than ca. 400 nm (the arbitrary threshold between ultraviolet and visible light) to about 600 nm, preferably to ca. 700 nm, as well as absorption of ultraviolet light ( ⁇ ⁇ 400 nm).
  • ⁇ wavelength range
  • the organic compound is a compound selected from the group encompassing: phthalic acid, 4-sulfophthalic acid, 4-amino-2-hydroxybenzoic acid, 3- hydroxy-2-naphthylic acid, salicylic acid, 6-hydroxysalicylic acid, 5-hydroxysalicylic acid, 5- sulfosalicylic acid, 3,5-dinitrosalicylic acid, disodium salt of l,4-dihydroxy-l,3- benzenedisulfonic acid, gallic acid, pyrogallol, 2,3-naphthalenediol, 4-methylcatechol, 3,5-di- iert-butylcatechol, p-nitrocatechol, 3,4-dihydroxy-L-phenylalanine (DOPA), rutin as well as ascorbic acid.
  • DOPA 3,4-dihydroxy-L-phenylalanine
  • the compound bound to the surface is a compound selected from the group encompassing: disodium salt of 4,5-dihydroxy-l,3-benzenedisulfonic acid, rutin and ascorbic acid.
  • composition according to the invention contains additionally a buffer, preferably isotonic, stabilizing pH value within the acceptable pharmaceutical range.
  • a buffer preferably isotonic, stabilizing pH value within the acceptable pharmaceutical range.
  • the composition according to the invention contains the surface modified nanocrystalline titanium dioxide within the concentration range of 0.02 to 1 g dm and hydrogen peroxide, preferably in the concentration range of 0.001 to 0.1 g dm .
  • composition according to the invention can additionally contain pharmaceutical carriers and excipients.
  • carriers and excipients the known carriers and excipients used in pharmacy, that are compatible with the active substance, can be applied.
  • the modified titanium dioxide characterized by particle size not exceeding 100 nm constitutes stable colloidal systems in solution of PBS buffer, retaining its photocatalytic activity.
  • the composition according to the invention constitutes a clear, transparent aqueous solution, containing hydrogen peroxide and nanocrystalline titanium dioxide, the surface of which has been modified with rutin, as the active substances, together with NaCl and phosphate buffer.
  • the composition according to the invention or the colloidal solution of titanium dioxide nanoparticles is prepared as a concentrate, preferably containing 40-50 times higher concentration of titanium dioxide as compared to its final concentration in the composition.
  • the concentrate should be diluted with water, preferably with aqueous buffer solution, isotonic aqueous solution, hydrogen peroxide and eventually other additives to the final concentration of all ingredients.
  • the composition according to the invention is used to the external use as a contact lens cleaning solution.
  • the composition can be used in the production of a preparation for sterilisation or disinfection, preferably in the production of a photosterilising, photobacteriocidal, photomycocidal, or photocatalytic preparation particularly designed for use in one of the following areas: cosmetology, dermatology, ophthalmology, laryngology, urology, gynaecology, rheumatology, oncology, surgery, veterinary medicine, dentistry, in particular for the sterilization of surfaces and glass or plastic elements, particularly contact lenses, medical catheters, glass and/or plastic conduits as well as other surfaces, the sterilization of which is desirable and/or required.
  • composition according to the present invention exhibits photocatalytic activity upon irradiation with visible light ( ⁇ > 400 nm; photocatalysis is the result of the absorption of visible light by the titanium surface complex of the charge-transfer type), as well as ultraviolet light ( ⁇ ⁇ 400 nm; photocatalysis is the result of the absorption of ultraviolet light by the titanium surface complex of the charge-transfer type or directly by titanium dioxide).
  • the irradiation generates so-called reactive oxygen species (OH * , 0 2 " ⁇ , H 2 0 2 , l 2 ).
  • Fig. 1 shows UV-vis absorption spectra of a colloidal solution of Ti0 2 nanocrystals modified respectively with compound K-1 (Table 2) (a), ascorbic acid (b) and rutin (c) (each concentration: 0.4 g dm );
  • Fig. 2 shows a TEM image recorded for the material K-l @Ti0 2 ;
  • Fig. 1 shows UV-vis absorption spectra of a colloidal solution of Ti0 2 nanocrystals modified respectively with compound K-1 (Table 2) (a), ascorbic acid (b) and rutin (c) (each concentration: 0.4 g dm );
  • Fig. 2 shows a TEM image recorded for the material K-l @Ti0 2 ;
  • Fig. 1 shows UV-vis absorption spectra of a colloidal solution of Ti0 2 nanocrystals modified respectively with compound K-1 (Table 2) (a), ascorbic acid (b) and rutin (c) (each concentration: 0.4
  • E. coli viability tests in the presence of a colloidal solution of Ti0 2 nanocrystals modified with K-1 (grey) and in the absence of the photocatalyst (black) (a) during irradiation with light ⁇ > 420 nm and (b) E. coli viability test results in the same system in the dark, as well as E. coli viability tests in the presence of a colloidal solution of Ti0 2 nanocrystals modified with ascorbic acid (squares) and in the absence of the photocatalyst (triangles) (c) upon irradiation with light ⁇ > 420 nm and (d) E. coli viability test results in the same system in the dark.
  • Figure 5 shows the results described in the Example 5 of the comparative tests of photoactivity of the composition according to the present invention, or its components, in the process of proteins oxidation.
  • Figure 6 shows the results described in the Example 6 of the comparative tests of photoactivity of the composition according to the present invention, or its components, in the process of bacteria inactivation.
  • Figure 7 presents the results of azure B photooxidation proving the unexpected synergy between activity of the photocatalyst and hydrogen peroxide.
  • Example 1 Production of a nanocrystalline photocatalyst active in visible light
  • the initial substrate for the synthesis of the materials in question is an unmodified nanocrystalline Ti0 2 , which may be produced according to various known procedures. One of them is proposed by Wang et al. (J. Phys. Chem. B, 2000, 104, 93-104). Particles of titanium dioxide Ti0 2 smaller than 100 nm (estimated using imaging with a transmission electron microscope) is modified on its surface directly via chemisorption of an organic compound selected from the group according to the present invention with the formation of charge- transfer complexes. Photoinduced electron transfer occurs between the organic compound molecule and the semiconductor particle.
  • a photoactive colloid according to the present invention is characterized by a high degree of dispersion and occurs in the form of a suspension or emulsion.
  • an appropriate buffer i.e. SSC or PBS
  • Ti0 2 nanocrystals modified with ascorbic acid or another organic compound according to the present invention may then be subjected to further modifications consisting of conjugation with a molecule increasing the specificity of their activity (i.e. an antibody, peptide, biotin or vitamins).
  • a molecule increasing the specificity of their activity i.e. an antibody, peptide, biotin or vitamins.
  • UV-vis spectrum of the KA@Ti0 2 material is shown in Figure lb. Like other materials (stable in acidic solutions) KA@Ti0 2 shows absorption of visible light up to ca. 600-700 nm. UV-vis spectrum of the rutin @Ti0 2 solution is shown in Fig lc. The material shows absorption of visible light to a wavelength of 600 nm.
  • Photodegradation tests were carried out with bovine serum albumin (as a model protein) upon visible light irradiation in the presence of nanocrystalline Ti0 2 modified by organic compound selected from the group according to the present invention.
  • the protein concentration in solution was monitored using semi-quantitative method of polyacrylamide gel electrophoresis under denaturing conditions (SDS-PAGE).
  • SDS-PAGE semi-quantitative method of polyacrylamide gel electrophoresis under denaturing conditions
  • the reaction mixtures irrespective of the modification of nanocrystalline Ti0 2 , were prepared as follows: A solution of modified Ti0 2 (in an amount to yield a final concentration of 0.4 mg/ml in terms of Ti0 2 ) was mixed with bovine albumin (final concentration 0.4 mg/ml) and water to a final volume of 2 ml.
  • Irradiation was performed using a high-pressure mercury lamp, HBO-500, as a light source and filters delivering light at a wavelength in the range 420-800 nm. Tests were performed in a quvette purged with a small stream of air during irradiation to ensure a constant oxygen level in solution. During the experiment, samples were taken and subjected to electrophoresis following denaturation in order to monitor the degree of albumin degradation. The electrophoresis was performed in a Laemmli system using a 10% separating gel and a 4% stacking gel. The results are shown in Fig. 3. Sample 0' corresponds to an image of 2 ⁇ g of protein.
  • the photodegradation assays of protein have confirmed the high level of photocatalytic activity of K-l @Ti0 2 upon visible light irradiation.
  • the compiled protein electrophoresis images show protein degradation over the exposure time in a sample containing the protein and modified titanium dioxide in water. In the spectral range of 400- 800 nm (Fig. 3a) one can observe a clear decrease of protein concentration during irradiation. In a narrower radiation ranges, 435-800 nm and 455-800 nm, the results are slightly poorer than the initial ones (Fig. 3b and 3c).
  • Protein photodegradation assays have confirmed the high level of photocatalytic activity of KA@Ti0 2 upon visible light irradiation. During irradiation within the spectral ranges 400-800 nm and 420-800 nm (Fig. 3d and 3e, respectively) a clear decrease in protein concentration can be observed within several minutes.
  • Protein photodegradation assays have confirmed the high level of photocatalytic activity of rutin @Ti0 2 upon visible light irradiation.
  • the compiled protein electrophoresis images show protein degradation over the exposure time in a sample containing the protein and modified titanium dioxide in water. Both in the spectrum range 420-800 nm (Fig. 3f) and in a narrower range of radiation, 455-800 nm (Fig. 3g) one can observe clear decrease in protein concentration throughout the time of exposure.
  • the assays of the ability of the new materials to photoinactivate microorganisms were performed on a model strain of Escherichia coli, and the absence of cytotoxicity in this material to this bacterial strain was demonstrated.
  • the tests assaying the efficiency of the photoinactivation of microorganisms were performed thusly: A suspension of bacteria in water (ca. 10 6 CFU/ml determined spectrophoto metrically) was supplemented with a colloidal solution of nanocrystalline Ti0 2 modified with an organic compound selected from the group according to the present invention, to its final concentration of 0.4 mg/ml.
  • the assays were performed under the same irradiation conditions as the protein photodegradation assays (2 ml samples, see above) using a cut-off filter ⁇ > 420 nm, aerating the sample during irradiation. Small samples were collected in order to evaluate the colony-forming potential of the examined strain. The colony formation ability was determined in dishes through the inoculation of 100 ⁇ aliquots of a serial dilution of the bacterial suspension onto minimal medium (DIFCO) and counting the colonies. The results are shown as cell survival fractions S/So.
  • Example 5 Comparison of activity of the composition according to the invention and composition without the additives active towards proteins
  • the activity of the mixture of the photocatalyst and hydrogen peroxide is considerably strengthened as compared to the separate use of the photocatalyst and hydrogen peroxide.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Eyeglasses (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)

Abstract

The invention relates to a composition, particularly in the form of liquid to be used externally as a rinsing contact lenses, containing nanocrystalline photocatalyst active in visible light, and optionally hydrogen peroxide.

Description

Composition in the form of liquid for maintenance of contact lenses and medical materials
The subject of the present invention is a composition, especially in the form of a liquid for an external use, for treatment and maintenance of contact lenses, containing nanocrystalline photocatalyst active upon visible light illumination and eventually hydrogen peroxide.
The goal of the present invention is to deliver a composition for the production of solutions exhibiting sterilizing properties upon irradiation with visible light and therefore suitable for maintenance of various materials, especially those requiring physiological use, as contact lenses, medical materials (catheters, bandages, syringes, etc.).
Unexpectedly, such a defined goal has been achieved by the present invention.
The subject of the present invention is the composition containing titanium dioxide Ti02 modified on its surface with an organic compound selected from a group encompassing: i. a compound described by the general formula:
(or -COOH) (or -COOH) where R denotes -H, -NH2, -NH3 + or -S03M, in which M denotes H+, K+, Na+, Li+, NH4 +,
ii. ascorbic acid,
iii. a compound described by the formula:
OH OH OH
and additionally preferably an aqueous solution of hydrogen peroxide.
Preferably, the composition according to the invention is in the form of liquid containing a colloidal solution in which the dispersed phase is composed of the surface modified nanoparticles of titanium dioxide characterized by the particle size lower than 100 nm, while the aqueous solution of hydrogen peroxide plays the role of the dispersion medium.
Preferably, the composition according to the present invention exhibits visible light absorption as well as photocatalytic activity in a wavelength range (λ) no smaller than ca. 400 nm (the arbitrary threshold between ultraviolet and visible light) to about 600 nm, preferably to ca. 700 nm, as well as absorption of ultraviolet light (λ < 400 nm).
Equally preferably, it exhibits photocatalytic activity upon irradiation with visible light (wavelengths λ higher than 400 nm).
Equally preferably, it exhibits photocatalytic activity upon irradiation with ultraviolet light (wavelengths λ below 400 nm).
Preferably, the organic compound is a compound selected from the group encompassing: phthalic acid, 4-sulfophthalic acid, 4-amino-2-hydroxybenzoic acid, 3- hydroxy-2-naphthylic acid, salicylic acid, 6-hydroxysalicylic acid, 5-hydroxysalicylic acid, 5- sulfosalicylic acid, 3,5-dinitrosalicylic acid, disodium salt of l,4-dihydroxy-l,3- benzenedisulfonic acid, gallic acid, pyrogallol, 2,3-naphthalenediol, 4-methylcatechol, 3,5-di- iert-butylcatechol, p-nitrocatechol, 3,4-dihydroxy-L-phenylalanine (DOPA), rutin as well as ascorbic acid.
Equally preferably, it exhibits stability in aqueous solutions at pH of about 7, and the compound bound to the surface (modifier) is a compound selected from the group encompassing: disodium salt of 4,5-dihydroxy-l,3-benzenedisulfonic acid, rutin and ascorbic acid.
Preferably, the composition according to the invention contains additionally a buffer, preferably isotonic, stabilizing pH value within the acceptable pharmaceutical range.
Preferably, the composition according to the invention contains the surface modified nanocrystalline titanium dioxide within the concentration range of 0.02 to 1 g dm and hydrogen peroxide, preferably in the concentration range of 0.001 to 0.1 g dm .
The composition according to the invention can additionally contain pharmaceutical carriers and excipients. As carriers and excipients the known carriers and excipients used in pharmacy, that are compatible with the active substance, can be applied.
In an exemplary composition the modified titanium dioxide characterized by particle size not exceeding 100 nm constitutes stable colloidal systems in solution of PBS buffer, retaining its photocatalytic activity. Preferably, the composition according to the invention constitutes a clear, transparent aqueous solution, containing hydrogen peroxide and nanocrystalline titanium dioxide, the surface of which has been modified with rutin, as the active substances, together with NaCl and phosphate buffer.
Preferably, the composition according to the invention or the colloidal solution of titanium dioxide nanoparticles is prepared as a concentrate, preferably containing 40-50 times higher concentration of titanium dioxide as compared to its final concentration in the composition. To obtain the final composition, the concentrate should be diluted with water, preferably with aqueous buffer solution, isotonic aqueous solution, hydrogen peroxide and eventually other additives to the final concentration of all ingredients.
Preferably, the composition according to the invention is used to the external use as a contact lens cleaning solution. In general, the composition can be used in the production of a preparation for sterilisation or disinfection, preferably in the production of a photosterilising, photobacteriocidal, photomycocidal, or photocatalytic preparation particularly designed for use in one of the following areas: cosmetology, dermatology, ophthalmology, laryngology, urology, gynaecology, rheumatology, oncology, surgery, veterinary medicine, dentistry, in particular for the sterilization of surfaces and glass or plastic elements, particularly contact lenses, medical catheters, glass and/or plastic conduits as well as other surfaces, the sterilization of which is desirable and/or required.
The composition according to the present invention exhibits photocatalytic activity upon irradiation with visible light (λ > 400 nm; photocatalysis is the result of the absorption of visible light by the titanium surface complex of the charge-transfer type), as well as ultraviolet light (λ < 400 nm; photocatalysis is the result of the absorption of ultraviolet light by the titanium surface complex of the charge-transfer type or directly by titanium dioxide). The irradiation generates so-called reactive oxygen species (OH*, 02 "~, H202, l 2).
Unexpectedly it has been shown, that addition of small amounts of peroxides, e.g. hydrogen peroxide, intensifies the photocatalytic properties of the photocatalyst described above. The electron transfer from the conduction band of titanium dioxide to the peroxide molecule leads to the formation of highly oxidative hydroxyl radicals as a consequence of the peroxide reduction. In the presence of trace amounts of metal ions a catalytic decomposition of H202 to OH' may occur; the reaction known as a Fenton process. This process unfavorably influences the stability and durability of the composition, however it can be inhibited by addition of agents complexing metal ions, e.g. EDTA (ethylenediaminetetraacetic acid or its salt), in amounts assuring binding of all transition metal ions present in the composition.
Example embodiments of the present invention have been shown in figures, in which Fig. 1 shows UV-vis absorption spectra of a colloidal solution of Ti02 nanocrystals modified respectively with compound K-1 (Table 2) (a), ascorbic acid (b) and rutin (c) (each concentration: 0.4 g dm ); Fig. 2 shows a TEM image recorded for the material K-l @Ti02; Fig. 3 shows the results of irradiation with visible light (using cut-off filters) of a reaction mixture (bovine albumin with a solution of colloidal Ti02 nanocrystals modified respectively with compound K-1, ascorbic acid and rutin), in the electrophoretic image: K-l @Ti02: (a) λ > 400 nm, (b) λ > 435 nm, (c) λ > 455 nm, KA@Ti02: (d) λ > 400 nm, (e) λ > 420 nm, rutin @Ti02: (f) λ > 420 nm, (g) λ > 455 nm; Fig. 4 shows E. coli viability tests in the presence of a colloidal solution of Ti02 nanocrystals modified with K-1 (grey) and in the absence of the photocatalyst (black) (a) during irradiation with light λ > 420 nm and (b) E. coli viability test results in the same system in the dark, as well as E. coli viability tests in the presence of a colloidal solution of Ti02 nanocrystals modified with ascorbic acid (squares) and in the absence of the photocatalyst (triangles) (c) upon irradiation with light λ > 420 nm and (d) E. coli viability test results in the same system in the dark. Figure 5 shows the results described in the Example 5 of the comparative tests of photoactivity of the composition according to the present invention, or its components, in the process of proteins oxidation. Figure 6 shows the results described in the Example 6 of the comparative tests of photoactivity of the composition according to the present invention, or its components, in the process of bacteria inactivation. Figure 7 presents the results of azure B photooxidation proving the unexpected synergy between activity of the photocatalyst and hydrogen peroxide.
Example 1. Production of a nanocrystalline photocatalyst active in visible light
The initial substrate for the synthesis of the materials in question is an unmodified nanocrystalline Ti02, which may be produced according to various known procedures. One of them is proposed by Wang et al. (J. Phys. Chem. B, 2000, 104, 93-104). Particles of titanium dioxide Ti02 smaller than 100 nm (estimated using imaging with a transmission electron microscope) is modified on its surface directly via chemisorption of an organic compound selected from the group according to the present invention with the formation of charge- transfer complexes. Photoinduced electron transfer occurs between the organic compound molecule and the semiconductor particle. A photoactive colloid according to the present invention is characterized by a high degree of dispersion and occurs in the form of a suspension or emulsion.
Variant 1. A colloidal aqueous solution of Ti02 (1.2 g drrf3) containing isopropanol (10%) in a nitric acid (HN03) environment (pH = 2.5) was supplemented with crystalline 4,5- dihydroxy-l,3-benzenedisulfonic acid disodium salt (K-l; Table 2) at a molar ratio of 1: 1 (modifier: Ti02). A yellow precipitate was formed. The resulting suspension was alkalized with an NaOH solution to pH = 7 (causing the precipitate to dissolve). The solution was placed in a dialysis tube and dialyzed twice against water or an appropriate buffer (i.e. SSC or PBS) in order to remove alcohol and the excess of modifier not bound with Ti02. A yellow, clear colloidal solution was produced, which was used in further experiments.
The method described is equally suitable for synthesizing nanocrystalline Ti02 modified with catechol derivatives or salicylic acid or phthalic acid derivatives (syntheses 2 and 3, Tables 1 and 2). In these cases it proved impossible to obtain stable materials (ones that do not undergo aggregation) at pH ~ 7.
Variant 2. A colloidal aqueous solution of Ti02 (1.2 g drrf3) containing isopropanol (10%) in a nitric acid environment (HNO3, pH = 2.5) was supplemented with a compound from the group A (A-l:A-2; phthalic acid derivatives) or S (S-l:S-7; salicylic acid derivatives; Table 1) in crystalline form, at a molar ratio of 1: 1 (modifier:Ti02). The colloidal solution changed its color. The resulting colloidal solution was alkalized with an NaOH solution to pH = 7. The solution was placed in a dialysis tube and dialyzed twice against water, in order to remove alcohol and any modifier not bound with Ti02. Table 1. Phthalic acid and salicylic acid derivatives.
Variant 3. A colloidal aqueous solution of T1O2 (1.2 g drrf3) containing isopropanol (10%) in a nitric acid environment (HNO3, pH = 2.5) was supplemented with a compound from the group K (K-2:K-8; Table 2) at a molar ratio of 1: 1 (modifier: Ti02). The colloidal solution changed its color. The resulting colloidal solution was alkalized with an NaOH solution to pH = 7. The solution was placed in a dialysis tube and dialyzed twice against water, in order to remove alcohol and any modifier not bound with Ti02. Table 2. Catechol derivatives.
arant . co o a aqueous souton o 2 . g m contanng sopropano in a nitric acid environment (HN03, pH = 2.5) was supplemented with a compound with the formula (rutin):
at a molar ratio of 1 : 1 (rutin:Ti02). An orange precipitate was formed. The resulting suspension was alkalized with an NaOH solution to pH = 9 (causing the precipitate to dissolve). The solution was placed in a dialysis tube and dialyzed three times. The first dialysis was performed against an aqueous solution of NaOH, pH = 9. The subsequent two dialyses were performed against distilled water, or appropriate buffer (i.e. SSC or PBS, pH ~ 7) in order to remove alcohol and any modifier not bound with Ti02. An orange, clear colloidal solution was obtained which was used in subsequent experiments.
Variant 4B. A colloidal aqueous solution of Ti02 (1.2 g dnT3) containing isopropanol (10%) in a nitric acid environment (HN03, pH = 2.5) was supplemented with a crystalline compound with the formula (rutin):
at a molar ratio of 1 : 1 (rutin:Ti02). An orange precipitate appeared. The resulting suspension was centrifuged. The precipitate was rinsed several times with an aqueous HC1 solution (pH = 2 to 4) until excess modifier (rutin) was rinsed out, which was confirmed spectrophotometrically. Next, the precipitate was suspended in water or a buffered aqueous solution. A clear, stable colloidal solution was produced.
Variant 5. A colloidal aqueous solution of Ti02 (1.2 g drrf3) containing isopropanol (10%) in a nitric acid environment (HN03, pH = 2.5) was supplemented with a crystalline ascorbic acid (KA) in a molar ratio 1: 1 (KA:Ti02); appearance of orange color was observed. Then, the resulting sol was adjusted to pH = 7 and placed in a dialysis bag and dialyzed twice against an aqueous solution of ascorbic acid (5 mmol dm , pH = 7). Orange, clear, colloidal solution was obtained, which was used in further experiments. Nanocrystals of Ti02 modified with ascorbic acid (KA@Ti02) were stable (did not undergo aggregation) at pH = 7.
Ti02 nanocrystals modified with ascorbic acid or another organic compound according to the present invention may then be subjected to further modifications consisting of conjugation with a molecule increasing the specificity of their activity (i.e. an antibody, peptide, biotin or vitamins).
Example 2 Characteristics of the synthesized materials
Within the group of materials synthesized as described in Example 1 Ti02 nanocrystals modified by modifier K-l (K-l @Ti02), rutin (rutin @Ti02) and ascorbic acid (KA@Ti02) showed stability at pH = 7. Other materials underwent aggregation, which was manifested in the precipitation at pH > 3-4. UV-vis spectrum of the K-l @Ti02 is shown in Fig la. Like other materials (stable in acidic solutions) it shows absorption of visible light up to ca. 500-700 nm. The transmission electron microscope image presented in Figure 2 confirms the homogeneity of the material - separated particles, showing no tendency to aggregate are several to twenty nanometers in size. UV-vis spectrum of the KA@Ti02 material is shown in Figure lb. Like other materials (stable in acidic solutions) KA@Ti02 shows absorption of visible light up to ca. 600-700 nm. UV-vis spectrum of the rutin @Ti02 solution is shown in Fig lc. The material shows absorption of visible light to a wavelength of 600 nm.
Example 3. Photocatalytic activity of the materials
Photodegradation tests were carried out with bovine serum albumin (as a model protein) upon visible light irradiation in the presence of nanocrystalline Ti02 modified by organic compound selected from the group according to the present invention. The protein concentration in solution was monitored using semi-quantitative method of polyacrylamide gel electrophoresis under denaturing conditions (SDS-PAGE). The reaction mixtures, irrespective of the modification of nanocrystalline Ti02, were prepared as follows: A solution of modified Ti02 (in an amount to yield a final concentration of 0.4 mg/ml in terms of Ti02) was mixed with bovine albumin (final concentration 0.4 mg/ml) and water to a final volume of 2 ml.
Irradiation was performed using a high-pressure mercury lamp, HBO-500, as a light source and filters delivering light at a wavelength in the range 420-800 nm. Tests were performed in a quvette purged with a small stream of air during irradiation to ensure a constant oxygen level in solution. During the experiment, samples were taken and subjected to electrophoresis following denaturation in order to monitor the degree of albumin degradation. The electrophoresis was performed in a Laemmli system using a 10% separating gel and a 4% stacking gel. The results are shown in Fig. 3. Sample 0' corresponds to an image of 2 μg of protein.
The photodegradation assays of protein have confirmed the high level of photocatalytic activity of K-l @Ti02 upon visible light irradiation. The compiled protein electrophoresis images show protein degradation over the exposure time in a sample containing the protein and modified titanium dioxide in water. In the spectral range of 400- 800 nm (Fig. 3a) one can observe a clear decrease of protein concentration during irradiation. In a narrower radiation ranges, 435-800 nm and 455-800 nm, the results are slightly poorer than the initial ones (Fig. 3b and 3c).
Protein photodegradation assays have confirmed the high level of photocatalytic activity of KA@Ti02 upon visible light irradiation. During irradiation within the spectral ranges 400-800 nm and 420-800 nm (Fig. 3d and 3e, respectively) a clear decrease in protein concentration can be observed within several minutes.
Protein photodegradation assays have confirmed the high level of photocatalytic activity of rutin @Ti02 upon visible light irradiation. The compiled protein electrophoresis images show protein degradation over the exposure time in a sample containing the protein and modified titanium dioxide in water. Both in the spectrum range 420-800 nm (Fig. 3f) and in a narrower range of radiation, 455-800 nm (Fig. 3g) one can observe clear decrease in protein concentration throughout the time of exposure.
Example 4. Evaluation of the activity of the material in the photoinactivation of bacteria
The assays of the ability of the new materials to photoinactivate microorganisms were performed on a model strain of Escherichia coli, and the absence of cytotoxicity in this material to this bacterial strain was demonstrated. The tests assaying the efficiency of the photoinactivation of microorganisms were performed thusly: A suspension of bacteria in water (ca. 106 CFU/ml determined spectrophoto metrically) was supplemented with a colloidal solution of nanocrystalline Ti02 modified with an organic compound selected from the group according to the present invention, to its final concentration of 0.4 mg/ml. The assays were performed under the same irradiation conditions as the protein photodegradation assays (2 ml samples, see above) using a cut-off filter λ > 420 nm, aerating the sample during irradiation. Small samples were collected in order to evaluate the colony-forming potential of the examined strain. The colony formation ability was determined in dishes through the inoculation of 100 μΐ aliquots of a serial dilution of the bacterial suspension onto minimal medium (DIFCO) and counting the colonies. The results are shown as cell survival fractions S/So.
The results obtained for K-l @Ti02 demonstrate its high activity in the photoinactivation of microorganisms, using the model strain of E. coli (Fig. 4a). At the same time, the cytotoxicity of the tested materials was not observed against this strain (Fig. 4b). Analogous results were obtained for KA@Ti02 (photoinactivation - Fig. 4c and cytotoxicity - Fig. 4d).
Example 5 . Comparison of activity of the composition according to the invention and composition without the additives active towards proteins
Photodegradation tests were carried out with bovine serum albumin (a protein as a model substrate) under visible light irradiation in the presence of the composition based on nanocrystalline Ti02 modified with rutin. The protein concentration in solution was monitored using semi-quantitative method of polyacrylamide gel electrophoresis under denaturing conditions (SDS-PAGE). The reaction mixtures, irrespective of the modification of nanocrystalline Ti02, were prepared as follows:
The solution of modified Ti02 (final concentration of 0.32 g dm in terms of Ti02), bovine serum albumin (final concentration of 0.2 g dm ) and water were mixed together to a final volume of 2 ml.
Tests were performed in chambers of 2 ml capacity using LEDs as the light source (λιηαχ = 470 nm, power of 30 mW). During the experiment, collected samples after protein denaturation were subjected to electrophoretic analysis to determine the extent of albumin degradation. Electrophoresis was performed using Laemni setup with 10% separating gel and 4% stacking gel. The results of measurements are presented in the following figures (sample 0' corresponds to the image of 1 μg of protein):
Figure 5a - rutin @Ti02 in PBS + irradiation 5 h Figure 5b - rutin @Ti02 in PBS + 2 mM H202 irradiation 5 h
Figure 5c - 3% H202 (after 5 h in the dark)
Example 6. Comparison of activity of the composition according to the invention with composition without active ingredients
To a suspension of bacterial strain (Escherichia coli) of various concentrations in PBS a sterile colloidal solution of rutin@Ti02 (filtered through a sterile syringe filter 0.20 μηι) was added (Fig. 6a) or a sterile solution of rutin@Ti02 with the addition of H202 (Fig. 6b) to reach its final concentration of 0.32 g dm (in terms of Ti02). Results were compared to the results obtained for a sterile solution of PBS (Fig. 6c).
Tests were performed in chambers of 2 ml capacity using LEDs as the light source (λιηαχ = 470 nm, power of 30 mW). Suspensions were irradiated for 5 h at ambient temperature. Small volumes of samples were collected to determine the ability of bacteria to form colonies after irradiation. Analogous control experiments were done in the dark. In this case chambers were incubated for 5h in dark at ambient temperature instead of their exposition to irradiation. Colony forming ability was determined by plating the 100 μΐ of serial dilutions of bacterial suspension to the minimum medium (Difco) and counting bacterial colonies after 24 h of bacterial growth on the solid medium at 37°C. Results were expressed as survival fraction S/So. The results prove very high activity of tested compositions towards photoinactivation of microorganisms (Fig. 6). No significant cytotoxicity of tested materials to bacterial strains was observed in the dark.
Example 7. Synergy of the photocatalyst and hydrogen peroxide
The study was performed using a model system in which the decomposition of the dye azur B was monitored. The results are presented in Figure 7. Photode gradation of azur B was observed in the presence of the photocatalyst rutin@Ti02 at the concentration of 0.32 g dm (squares), hydrogen peroxide at the concentration of 5 mmol dm (triangles) and the mixture of the photocatalyst and hydrogen peroxide at the above mentioned concentrations (circles). The experiment was conducted under the following conditions: initial concentration of azur B was 0.8x10^ mol dm 3, irradiation with the high-pressure mercury lamp HBO-500 equipped with the 420 nm cut-off filter (exposure 420 < λ < 800 nm).
Surprisingly, the activity of the mixture of the photocatalyst and hydrogen peroxide is considerably strengthened as compared to the separate use of the photocatalyst and hydrogen peroxide.

Claims

Claims
1. The composition, characterized in that it contains surface-modified titanium dioxide Ti02 with an organic compound selected from a group encomassing:
i. a compound with the formula:
(or -COOH) (or -COOH) where R denotes -H, -NH2, -NH3 + or -S03M, in which M denotes H+, K+, Na+, Li+, NH4 +, ii. ascorbic acid,
iii. a compound with the formul
and preferably an aqueous solution of hydrogen peroxide.
2. Composition according to claim 1, characterized in that it is in the form of liquid containing colloidal solution, with surface-modified titanium dioxide nanoparticles smaller than 100 nm as a dispersed phase, and the solution of hydrogen peroxide as the dispersing medium.
3. Composition according to the claim 1, characterized in that it shows visible light absorption in the wavelength range (λ) of not less than approximately 400 nm to about 600 nm, preferably up to about 700 nm, and ultraviolet light absorption (λ < 400 nm).
4. Composition according to the claim 1, characterized in that the organic compound is a compound selected from the group consisting of: phthalic acid, 4-sulfophthalic acid, 4-amino- 2-hydroxybenzoic acid, 3-hydroxy-2-naphthylic acid, salicylic acid, 6-hydroxysalicylic acid, 5-hydroxysalicylic acid, 5-sulfosalicylic acid, 3,5-dinitrosalicylic acid, disodium salt of 1,4- dihydroxy-l,3-benzenedisulfonic acid, gallic acid, pyrogallol, 2,3-naphthalenediol, 4- methylcatechol, 3,5-di-ie/t-butylcatechol, p-nitrocatechol, 3,4-dihydroxy-L-phenylalanine (DOPA), rutin and ascorbic acid.
5. Composition according to the claim 2, characterized in that it exhibits stability in aqueous solution with a pH of about 7, and the organic compound is a compound selected from the group consisting of: disodium salt of 4,5-dihydroxybenzene-l,3-disulfonic acid, rutin or ascorbic acid.
6. Composition according to the claim 1, characterized in that it additionally contains a buffer system, preferably isotonic, to maintain the pH in a pharmaceutically acceptable range.
7. Composition according to the claim 6, characterized in that it contains surface-modified nanocrystalline titanium dioxide within the concentration range of 0.02 g dm —3 to 1 g dm—3 , hydrogen peroxide, preferably in the amount within the range of 0.001 g dm —3 to 0.1 g dm—3 , and a stabilizer of hydrogen peroxide, preferably EDTA.
8. Composition according to the claims 6 or 7, characterized in that it contains additionally an additive showing bacteriocidal and/or mycocidal activity.
EP11727815.0A 2010-04-26 2011-04-23 Composition in the form of liquid for maintenance of contact lenses and medical materials Not-in-force EP2563148B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL391056A PL229207B1 (en) 2010-04-26 2010-04-26 Liquid composition for contact lens and medical materials care
PCT/PL2011/050011 WO2011136672A1 (en) 2010-04-26 2011-04-23 Composition in the form of liquid for maintenance of contact lenses and medical materials

Publications (2)

Publication Number Publication Date
EP2563148A1 true EP2563148A1 (en) 2013-03-06
EP2563148B1 EP2563148B1 (en) 2016-08-24

Family

ID=44627473

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11727815.0A Not-in-force EP2563148B1 (en) 2010-04-26 2011-04-23 Composition in the form of liquid for maintenance of contact lenses and medical materials

Country Status (12)

Country Link
US (1) US20130122073A1 (en)
EP (1) EP2563148B1 (en)
JP (1) JP5902672B2 (en)
KR (1) KR101841303B1 (en)
AU (1) AU2011245778A1 (en)
BR (1) BR112012027497B1 (en)
CA (1) CA2797491C (en)
ES (1) ES2601627T3 (en)
MX (1) MX340755B (en)
PL (2) PL229207B1 (en)
RU (1) RU2581827C2 (en)
WO (1) WO2011136672A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20120171A1 (en) * 2012-02-08 2013-08-09 Alessio Gerardo Maugeri PLANTS FOR NANOMATERIAL INCLUDING FLUIDS
ITMI20120172A1 (en) * 2012-02-08 2013-08-09 Alessio Gerardo Maugeri OPHTHALMIC AND NANOMATERIAL DEVICES
PL229321B1 (en) * 2012-07-23 2018-07-31 Univ Jagiellonski TiO2 photocatalytic coating on the surfaces of polymer, visible light activated, process for their preparation and the use thereof
ITAR20130026A1 (en) * 2013-07-16 2015-01-17 A Chi Mo S R L DISINFECTANT FOR WATER, IN PARTICULAR FOR THE WATER OF THE POOLS, AND ITS PRODUCTION METHOD.
CN103439448B (en) * 2013-07-25 2015-07-15 闽南师范大学 Method used for rapid separation and detection of organophosphorus pesticides in water
SE2150715A1 (en) * 2021-04-23 2022-10-24 Aurena Laboratories Holding Ab Transition metal oxide adducts for regulated generation of reactive oxygen species

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003093481A (en) * 2001-09-25 2003-04-02 Menicon Co Ltd Sterilizing and disinfecting device for contact lens
JP2005211545A (en) * 2004-02-02 2005-08-11 Toyota Central Res & Dev Lab Inc Disinfection method and disinfectant solution for contact lens
US20070078190A1 (en) * 2005-09-30 2007-04-05 Distefano Frank V Use of 2,3-dihydroxynaphthalene-6-sulfonic acid salts as dispersants
CN101028528A (en) * 2006-02-27 2007-09-05 权力敏 Biological light catalyst
EP2059267B1 (en) * 2006-08-16 2012-04-18 Novartis AG Temporal photo-bleaching of colored lens care solutions
AT504151A1 (en) * 2006-08-17 2008-03-15 Alfred Konzett MEDICINAL PRODUCT, USE OF A PHOTOREACTIVE AGENT FOR THE MANUFACTURE OF SUCH A MEDICAMENT AND TREATMENT AGENT FOR THE TREATMENT OF SURFACE MUSHROOMS, BACTERIA AND VIRUS DISEASES USING SUCH A MEDICAMENT
WO2010098687A2 (en) * 2009-02-26 2010-09-02 Uniwersytet Jagielloński Nanocrystalline photocatalytic colloid, a method of producing it and its use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2011136672A1 *

Also Published As

Publication number Publication date
WO2011136672A1 (en) 2011-11-03
ES2601627T3 (en) 2017-02-15
MX2012012532A (en) 2013-05-09
RU2012145755A (en) 2014-06-10
AU2011245778A1 (en) 2012-11-15
JP2013525426A (en) 2013-06-20
PL229207B1 (en) 2018-06-29
US20130122073A1 (en) 2013-05-16
RU2581827C2 (en) 2016-04-20
BR112012027497A2 (en) 2018-08-07
EP2563148B1 (en) 2016-08-24
JP5902672B2 (en) 2016-04-13
PL2563148T3 (en) 2017-02-28
MX340755B (en) 2016-07-25
CA2797491C (en) 2018-01-02
KR101841303B1 (en) 2018-03-22
CA2797491A1 (en) 2011-11-03
KR20130058691A (en) 2013-06-04
BR112012027497B1 (en) 2019-09-24

Similar Documents

Publication Publication Date Title
Chu et al. Near-infrared carbon dot-based platform for bioimaging and photothermal/photodynamic/quaternary ammonium triple synergistic sterilization triggered by single NIR light source
Stanić et al. Antibacterial activity of metal oxide nanoparticles
Bhattacharya et al. Fabrication of magnesium oxide nanoparticles by solvent alteration and their bactericidal applications
Besinis et al. The antibacterial effects of silver, titanium dioxide and silica dioxide nanoparticles compared to the dental disinfectant chlorhexidine on Streptococcus mutans using a suite of bioassays
EP2563148B1 (en) Composition in the form of liquid for maintenance of contact lenses and medical materials
Ran et al. Photocatalytic antimicrobials: principles, design strategies, and applications
Zhao et al. Antibacterial carbon dots: mechanisms, design, and applications
Arularasu et al. Synthesis and characterization of cellulose/TiO2 nanocomposite: Evaluation of in vitro antibacterial and in silico molecular docking studies
Golmohamadpour et al. Antimicrobial photodynamic therapy assessment of three indocyanine green-loaded metal-organic frameworks against Enterococcus faecalis
Putri et al. Highly antimicrobial activity of cerium oxide nanoparticles synthesized using Moringa oleifera leaf extract by a rapid green precipitation method
Fullriede et al. pH-responsive release of chlorhexidine from modified nanoporous silica nanoparticles for dental applications
CA2624274A1 (en) Silver/water, silver gels and silver-based compositions; and methods for making and using the same
Swaminathan et al. Antimicrobial activity of the engineered nanoparticles used as coating agents
EP2421644B1 (en) Nanocrystalline photocatalytic colloid, a method of producing it and its use
RU2445951C1 (en) Method of producing concentrates of zerovalent metal dispersions with antiseptic properties
CN102847193A (en) Chitosan fluid dressing film
Elamin et al. Pluronic f127 encapsulated titanium dioxide nanoparticles: evaluation of physiochemical properties for biological applications
EP2814319B1 (en) Antimicrobial composition containing photochemically stable silver complexes
Deepika et al. Microwave-assisted hydrothermal synthesis of ZnO@ ZrO2 nanohybrid for biomedical and photocatalytic applications
AU2015215866B2 (en) Composition in the form of liquid for maintenance of contact lenses and medical materials
CN109221102A (en) A kind of antibacterial new material
JP5296463B2 (en) Antibacterial agent
JP2005289660A (en) Surface-modified titanium dioxide particulate and dispersion thereof and method for manufacturing the same
JP2008013492A (en) Preservative for cosmetic, cosmetic
KR100770358B1 (en) Non-toxic colloid silver peroxide solution for sterillization, antigerms and deodorization

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20121126

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20150629

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160316

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 822201

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160915

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602011029610

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 822201

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160824

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161124

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2601627

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20170215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161125

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161226

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602011029610

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161124

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20170526

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20170421

Year of fee payment: 7

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20170423

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170423

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170430

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170430

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170423

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20180423

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170423

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20110423

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160824

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602011029610

Country of ref document: DE

Representative=s name: ZWICKER SCHNAPPAUF & PARTNER PATENTANWAELTE PA, DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190423

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180423

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20200312

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161224

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20200407

Year of fee payment: 10

Ref country code: ES

Payment date: 20200516

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20200423

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20210414

Year of fee payment: 11

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20210501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210501

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20220727

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210424

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602011029610

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221103

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200423